Core Insights - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [1][2]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue after conducting evaluations of historical collection trends [3]. - The company also increased its professional liability reserves by $54 million due to adverse claim developments from 2019 to 2022 and broader industry trends [3]. - Following these disclosures, Ardent's stock price dropped over 33% on November 13, 2025 [3].

Core Viewpoint - The Schall Law Firm is investigating potential securities law violations by Ardent Health, Inc., focusing on misleading statements and undisclosed information that may have affected investors [2]. Financial Impact - Ardent Health, Inc. reported a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves in its Q3 2025 financial results [2]. - Following this announcement, Ardent's shares fell nearly 34% the next day [2]. Legal Action - The Schall Law Firm is encouraging shareholders who suffered losses to participate in the investigation and discuss their rights [3].

Core Viewpoint - Ardent Health's Q3 2025 financial results significantly disappointed investors, leading to a 33% drop in share price after missing consensus EPS estimates and revealing adverse non-recurring items [1][4]. Financial Performance - The company reported an EPS of -$0.17, a decrease of 189% compared to the same period last year, which was well below market expectations [4]. - A $43 million adjustment was made that reduced revenue for the quarter due to a change in the estimation technique for accounts receivable collectability [4]. - Ardent Health increased its professional and general liability reserves by $54 million, attributed to adverse developments in prior period claims related to settlements and ongoing litigation [5]. - The adjusted EBITDA guidance for 2025 was significantly lowered to $530-$550 million from a previous range of $575-$615 million, marking a 9% decrease at the midpoint [5]. Market Reaction - Following the disappointing financial results, Ardent Health's share price fell sharply, reflecting investor concerns over the company's financial health and operational issues [5]. Legal Investigation - Hagens Berman, a shareholder rights law firm, has initiated an investigation into potential violations of federal securities laws by Ardent Health, focusing on the accuracy of the company's financial statements and internal controls [2][3]. - The investigation aims to determine if company leadership was aware of issues related to revenue accounting and whether the reserve increase was timely [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Ardent Health, Inc. for possible violations of federal securities laws and unlawful business practices following significant financial disclosures [1][2]. Investigation Details - On November 12, 2025, Ardent announced a $43 million reduction in revenue due to changes in accounting estimates regarding accounts receivable collectability [2]. - The company also reported a $54 million increase in professional liability reserves related to claims in New Mexico [2]. - Following these announcements, Ardent's stock price fell by $4.75, approximately 33.8%, from $14.05 to $9.30 per share [2]. Next Steps - Investors who purchased Ardent shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a law firm with a national presence, representing individual and institutional investors in various types of litigation, including securities and consumer protection [4].

Core Insights - Ardent Health, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - The company reported a $43 million reduction in revenue and a $54 million increase in professional liability reserves in its Q3 2025 financial results [2] - Following the announcement, Ardent's stock experienced a significant decline during pre-market trading [3] Financial Performance - Ardent Health disclosed a $43 million decrease in revenue due to changes in accounting estimates related to accounts receivable [2] - The company also reported a $54 million increase in professional liability reserves for claims in New Mexico [2] Market Reaction - The announcement of the financial results led to a notable drop in Ardent's common stock during pre-market trading on November 13, 2025 [3]

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [4]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in revenue for Q3 2025 after conducting evaluations of historical collection trends [5]. - The company increased its professional liability reserves by $54 million due to adverse claim developments from 2019 to 2022 and broader industry trends [5]. - Following the financial disclosures, Ardent's stock price dropped over 33% during trading on November 13, 2025 [5]. Legal Context - The investigation is being led by Bleichmar Fonti & Auld LLP, a law firm specializing in securities class actions [2][7]. - Investors are encouraged to seek legal options and submit their information to the firm, which operates on a contingency fee basis [6].

Ardent Health (NYSE:ARDT) FY Conference November 18, 2025 11:00 AM ET Company ParticipantsAlfred Lumsdaine - CFOMarty Bonick - President and CEOConference Call ParticipantsRaj Kumar - Healthcare Services AnalystRaj KumarAll right, so we're here at the top of the hour, so we're just going to get started. Welcome to Day One of the Stephens 2025 Annual Investment Conference, live and in person in Nashville. I'm Raj Kumar, Healthcare Services Analyst with Stevens. For our next panel, we have Ardent Health. Arde ...

Group 1 - Diodes (DIOD) is a leading manufacturer and supplier of high-quality discrete and analog semiconductor products, primarily serving the communications, computing, industrial, consumer electronics, and automotive markets [1] - The Zacks Consensus Estimate for Diodes' current year earnings has been revised 12.2% downward over the last 60 days [1] Group 2 - Ardent Health, Inc. (ARDT) is a provider of healthcare services [2] - The Zacks Consensus Estimate for Ardent Health's current year earnings has been revised almost 8.8% downward over the last 60 days [2] Group 3 - F5 (FFIV) provides products and services to manage Internet traffic worldwide [2] - The Zacks Consensus Estimate for F5's current year earnings has been revised almost 6.3% downward over the last 60 days [2]

Core Insights - Ardent Health, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - The company reported a $43 million reduction in revenue and a $54 million increase in professional liability reserves in its Q3 2025 financial results [2] - Following the financial disclosures, Ardent's stock experienced a significant decline during pre-market trading [3] Financial Performance - Ardent Health disclosed a $43 million decrease in revenue due to changes in accounting estimates regarding accounts receivable [2] - The company also announced a $54 million increase in professional liability reserves related to claims in New Mexico [2] Market Reaction - The stock price of Ardent Health fell significantly in pre-market trading on November 13, 2025, following the release of its financial results [3]

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price, which fell over 33% after the company reported disappointing Q3 2025 financial results [1][3][4]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue due to "hindsight evaluations of historical collection trends" [4]. - The company also increased its professional liability reserves by $54 million, citing "adverse prior period claim developments" related to claims from 2019 to 2022 and broader industry trends [4]. Stock Market Reaction - Following the financial disclosures on November 12, 2025, Ardent's stock price plummeted over 33% during trading on November 13, 2025 [4]. Legal Implications - Bleichmar Fonti & Auld LLP has initiated an investigation into Ardent Health, encouraging investors to seek additional information regarding potential legal options [1][5].